Duchenne muscular dystrophy (DMD), a severe X-linked recessive disorder which results in progressive muscle degeneration, is due to a lack of dystrophin, a membrane cytoskeletal protein. An approach to treatment is to compensate for dystrophin loss with utrophin, another cytoskeletal protein with over 80% homology with dystrophin. Utrophin is expressed, at the neuromuscular junction, in normal and DMD muscles and there is evidence that it may perform the same cellular functions as dystrophin. So, the identification of molecules or drugs that could up-regulate utrophin is a very important goal for therapy. We show that in adult normal and mdx mice (an animal model of Duchenne myopathy) treated with L-arginine, the substrate of nitric oxide synthase (NOS), a pool of utrophin localized at the membrane appeared and increased, respectively. In normal and mdx myotubes in culture, L-arginine, nitric oxide (NO), or hydroxyurea increased utrophin levels and enhanced its membrane localization. This effect did not occur with D-arginine, showing the involvement of NOS in this process. The NO-induced increase in utrophin was prevented by oxadiazolo-quinoxalin-1-one, an inhibitor of a soluble guanylate cyclase implicated in NO effects. These results open the way to a potential treatment for Duchenne and Becker dystrophies.
INTRODUCTION
Duchenne muscular dystrophy (DMD) (Engel et al., 1994) , the most frequent (1 boy in 3500) and severe myopathy, is characterized by progressive loss of muscular strength, ultimately leading to marked fibrosis and fatty infiltration. The DMD gene (Monaco et al., 1986) spans some 2300 kb on chromosome Xp21 and most of the DMD mutations are intragenic deletions, leading to the absence of dystrophin, a 427-kDa protein, in muscle of patients (Hoffman et al., 1987; Ahn & Kunkel, 1993) . Dystrophin is a large cytoskeletal protein localized at the inner surface of the sarcolemma in normal muscle. It is associated with a complex of glycoproteins and membrane proteins respectively called DAGs (dystrophin-associated glycoproteins) and DAPs (dystrophin-associated proteins), which are greatly reduced in DMD muscle (Appel et al., 1995; Ozawa et al., 1995) . One of the proteins, syntrophin, is associated to nitric oxide synthase (NOS) through a PDZ domain (Brenman et al., 1996) . The dystrophinglycoprotein complex links the subsarcolemmal cytoskeleton to the extracellular matrix. Dystrophin is involved in the maintenance of the morphological and functional structure of the striated muscle fiber and in calcium homeostasis.
A 13-kb autosomal transcript encoded by a gene of the long arm of chromosome 6 in human and chromosome 10 in mouse has been identified. It encodes a protein with over 80% homology with dystrophin, called utrophin (395 kDa) (Love et al., 1986; Tinsley et al., 1993) . The homology between dystrophin and utrophin extends over their whole lengths, suggesting that they derive from a common ancestral gene. Utrophin, like dystrophin, binds actin by the N-terminal, and the C-terminal domain is highly conserved. Utro-
